DCGI approved Kokate panel’s procedure for subsequent applicants for FDCs

  • News
  • June 30, 2017

New Delhi: Kokate Committee’s rational, a set of procedures has been approved and issued for subsequently fixed dose combinations (FDCs) applicants by The Drugs Controller General India (DCGI).

DCGI also released notice to instruct applicants to submit the application with relevant information and mention “Not applicable” for non-applicable boxes mentioned in Form 44.

Manufacturers, who have holding approved licenses from SLA (State Licensing Authority) needs to submit the documents; duly filled, signed and stamped Form 44; Rs. 15,000 duly signed treasury challan by Bank of Baroda; Composition and name of the FDC; product permission issued by SLA and copy of manufacturing license in Form 25/28; FDCs permitted for continued manufacturing & marketing under 18 months policy decision; SI No. of the FDC as per the list available on website, and name of FDC.

The notice clearly mentioned that 4 months of the time given to the manufacturers with valid SLA for such FDCs but not have approved NOC have to submit their applications to the Directorate as soon as possible within 4 months and if they fail then the license will be considered as without legal validity.

Stakeholders requested DCGI to specify the number of the minimum documents required.

  • Related Posts

    13 Years after Oxytocin Order, HC Seeks Compilance Status

    GWALIOR: The Gwalior Bench of the Madhya Pradesh High Court has directed the state government to submit a comprehensive compliance status report. This order addresses the implementation of the court’s…

    Centre Pushes Haryana to Fast-Track AIIMS Rewari

    New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    GLP-1 injections recalled across the US over sterility concerns

    GLP-1 injections recalled across the US over sterility concerns

    Govt allows third-party agencies to conduct departmental inspections

    Govt allows third-party agencies to conduct departmental inspections

    Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

    Fridge-free vaccines could reach more people, but there are still practical challenges in African settings